Cargando…
NF-κB: a new player in angiostatic therapy
Angiogenesis is considered a promising target in the treatment of cancer. Most of the angiogenesis inhibitors in late-stage clinical testing or approved for the treatment of cancer act indirectly on endothelial cells. They either neutralize angiogenic growth factors from the circulation or block the...
Autores principales: | Tabruyn, Sebastien P., Griffioen, Arjan W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268731/ https://www.ncbi.nlm.nih.gov/pubmed/18283548 http://dx.doi.org/10.1007/s10456-008-9094-4 |
Ejemplares similares
-
Angiostatic vaccines, an underestimated approach of cancer therapy
por: Griffioen, Arjan W.
Publicado: (2014) -
Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis
por: Sabatel, Céline, et al.
Publicado: (2010) -
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2012) -
Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
por: Weiss, Andrea, et al.
Publicado: (2015) -
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy
por: Weiss, Andrea, et al.
Publicado: (2015)